Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Reviews

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Published online: 04 January 2019; doi:10.1038/s41573-018-0008-x

The transcription factor NRF2 and its repressor KEAP1 have been implicated in the development and progression of chronic diseases. Here, Dinkova-Kostova and colleagues provide an overview of the physiological and pathological roles of NRF2, present emerging pharmacological modulators of the NRF2–KEAP1 axis and highlight associated drug development challenges.

Articles You May Like

If you find cats antisocial, it’s more likely you being a jerk, according to science
Does Cannabis Use Cause Schizophrenia?
Physicists have built a machine that actually breaks two rules of light
Orca Calf Offers Hope for a Fading Group in the Pacific Northwest
SMoLR: visualization and analysis of single-molecule localization microscopy data in R

Leave a Reply

Your email address will not be published. Required fields are marked *